Dexcom Promotes Jereme Sylvain to COO
Analysis based on 6 articles · First reported Sep 14, 2026 · Last updated Sep 15, 2026
The promotion is an internal leadership change that consolidates operational and financial oversight under one executive, signaling organizational streamlining rather than a material change to Dexcom's fundamentals. Market reaction was modestly positive, with shares closing up 1.99 percent on the Nasdaq, reflecting limited but favorable investor sentiment toward the management transition.
DexCom Inc. (DXCM), a medical device company, announced the promotion of Jereme Sylvain to the role of Chief Operating Officer, in addition to his existing duties as Chief Financial Officer. In this expanded role, Sylvain will assume oversight of Dexcom's global operations and quality teams, driving greater alignment, speed, and accountability across the company as it executes on its vision for growth and commitment to operational excellence. Sylvain joined Dexcom in 2018 and has served as Executive Vice President and Chief Financial Officer since 2021. According to Dexcom, Sylvain brings a combination of strategic judgment, operational discipline, and commitment to customers that are key for Dexcom's next phase of growth and scale. Jake Leach, President and CEO of Dexcom, stated that Sylvain's deep understanding of the business, operational discipline, and customer focus make him the right leader for this expanded role, and expressed confidence that Sylvain will help the company scale more effectively as it advances its goal to empower millions more people to take control of health. On the Nasdaq, Dexcom shares closed Monday's regular trading at $84.68, up 1.99 percent.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard